Making The Switch: Complete Wegovy vs Mounjaro Guide
Why Consider Changing From Wegovy To Mounjaro In The UK?
The decision to change from Wegovy to Mounjaro typically stems from several clinical considerations that patients discuss with their prescribers. Mounjaro (tirzepatide) offers a dual-action mechanism targeting both GIP and GLP-1 receptors, compared to Wegovy's single GLP-1 action, potentially providing different therapeutic benefits for some patients. Some individuals may experience better tolerability with Mounjaro's unique mechanism, whilst others might prefer the alternative dosing schedule or injection experience.
Supply availability has also influenced treatment decisions, though both medications are currently in stock at EverydayMeds with reliable UK distribution. Your prescriber can evaluate whether changing from Wegovy to Mounjaro aligns with your weight management goals, medical history, and individual response patterns. The transition requires careful clinical oversight to ensure appropriate dosing adjustments and continued treatment efficacy.
Wegovy vs Mounjaro: Pricing And Value Comparison
When evaluating the change from Wegovy to Mounjaro, cost considerations play a significant role in treatment selection. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Mounjaro follows a different pricing structure with its own dose escalation pathway, both requiring prescription-only access through qualified healthcare providers.
EverydayMeds offers bundle options for both treatments to support consistent therapy - the Wegovy Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, whilst the Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. New customers can apply discount code FIRST40 at checkout, with returning customers using code DOSE25. Both medications represent significant investments in long-term weight management, with clinical assessment fees and ongoing monitoring costs factored into your treatment journey.
Clinical Evidence: Understanding The Science Behind Each Treatment
Wegovy demonstrated substantial efficacy in the STEP clinical trial programme, with participants achieving approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). The medication's GLP-1 receptor agonist action may help reduce appetite and promote satiety through central nervous system pathways. Patients considering changing from Wegovy to Mounjaro should understand that direct head-to-head comparison data remains limited due to different trial populations and methodologies.
Mounjaro's dual GIP/GLP-1 receptor agonism represents a novel therapeutic approach, though both treatments require prescription-only access and specialist oversight. The decision to change from Wegovy to Mounjaro should be based on individual clinical response, tolerability profiles, and prescriber assessment rather than comparative trial percentages. Both medications carry MHRA additional monitoring status, reflecting their importance in obesity medicine and ongoing safety surveillance.
How Wegovy Works: Mechanism For Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of naturally occurring incretin hormones produced in your intestine. The medication works by binding to GLP-1 receptors in the brain's appetite control centres, potentially reducing food cravings and promoting earlier feelings of fullness during meals. This mechanism may help patients consume fewer calories naturally, supporting weight loss when combined with dietary modifications and increased physical activity. Wegovy also slows gastric emptying, which can contribute to prolonged satiety and reduced between-meal snacking. The once-weekly injection provides consistent therapeutic levels, designed to support sustainable weight management rather than rapid short-term losses. Understanding this mechanism helps explain why gradual dose escalation from 0.25mg to 2.4mg is essential for both efficacy and tolerability.
Complete Ordering Process: From Assessment To Delivery
Changing from Wegovy to Mounjaro through EverydayMeds begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and previous treatment responses. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring appropriate clinical oversight for this prescription-only medicine transition. Once approved, your chosen treatment ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for medication stability. All orders include detailed injection instructions, storage guidelines, and direct access to our clinical support team for ongoing questions. The process ensures full regulatory compliance with MHRA requirements whilst providing convenient access to both treatment options from our GPhC-registered pharmacy (#9012878). Payment is secured through encrypted channels, with discount codes applied automatically at checkout to reach the advertised pricing.
Storage Requirements And Practical Considerations
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, though they differ in room temperature stability once removed from the fridge. Wegovy offers superior travel convenience with 6 weeks of room temperature stability (below 30°C), compared to Mounjaro's 21-day limit, making it advantageous for extended trips or lifestyle flexibility. The FlexTouch pen system used by Wegovy provides intuitive injection experience with clear dose confirmation and ergonomic design. Dose escalation protocols differ between treatments - Wegovy follows a structured 16-week escalation to 2.4mg maintenance, whilst Mounjaro uses its own titration schedule. Both medications require consistent weekly injection timing, though the specific day can be adjusted if needed with prescriber guidance. Proper disposal of used pens through sharps bins or pharmacy return programmes ensures environmental responsibility and medication safety.
Supply Chain Reliability For Changing From Wegovy To Mounjaro
EverydayMeds maintains robust stock levels for both Wegovy and Mounjaro through direct manufacturer relationships with Novo Nordisk and Eli Lilly respectively. Our inventory management systems track all five Wegovy doses (0.25mg through 2.4mg) alongside complete Mounjaro ranges, ensuring patients considering the change from Wegovy to Mounjaro have immediate access to either option. Unlike some providers experiencing intermittent shortages, our pharmaceutical partnerships assurance consistent UK supply chains without waitlists or treatment delays.
The ability to switch between treatments without supply-related interruptions provides clinical flexibility for prescribers managing patient care. Both medications arrive through temperature-controlled logistics networks, maintaining cold-chain integrity from manufacturer to patient doorstep. This reliable access removes supply anxiety from treatment decisions, allowing purely clinical considerations to guide the choice between Wegovy and Mounjaro therapy paths.
Making Your Decision: Expert Support And Next Steps
The choice to change from Wegovy to Mounjaro represents a significant clinical decision requiring qualified medical oversight and individualized assessment. EverydayMeds provides comprehensive prescriber consultations to evaluate your specific circumstances, treatment history, and therapeutic goals before recommending either pathway. Our clinical team considers factors including previous medication responses, side effect profiles, lifestyle requirements, and long-term weight management objectives when supporting treatment transitions. Both medications remain available through our secure ordering system with immediate stock availability and next-day delivery options. Whether continuing with Wegovy or transitioning to Mounjaro, consistent clinical monitoring ensures optimal outcomes and medication safety. Begin your assessment today using discount code FIRST40 for new customers or DOSE25 for existing patients at https://everydaymeds.co.uk/collections/wegovy to explore both treatment options with expert guidance.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
